November 5, 2020 -- Eurofins contract development and manufacturing organization (CDMO) has expanded its existing drug product operation capabilities with a new manufacturing facility in Mississauga, Canada.
The expansion spans a 14,500-sq-ft facility equipped with preformulation and formulation laboratories, a development suite, multiple good manufacturing practice (GMP) manufacturing suites, clinical packaging space, and warehouse. The new facility will allow the company to offer all drug development services in a single location.
With the expansion, Eurofins CDMO can support development and clinical manufacturing of oral solid dosage forms, including highly potent active pharmaceutical ingredients (APIs). The integration of the new drug product operations complements Eurofins' existing API development and manufacturing services by providing "quick-to-clinic" drug product strategy to help clients meet phase I/II products.
The new expansion will enhance Eurofins' drug product performance of APIs, from investigational new drug-enabling through to late-stage programs.